ipratropium bromide / Generic mfg. - LARVOL DELTA

Intrapulmonary Percussive Ventilation (IPV) and Lung Compliance in Invasively Ventilated Children (SCCM 2026) - "90% were prescribed additional ACTs, most commonly albuterol (88%), 3% saline (65%), and ipratropium (41%), and 53% were co-administered with IPV.There was no significant percent change from baseline Cdyn at 15 minutes (5.5%, p=0.246) or 3 hours (5.8%, p=0.353), nor was there a difference within the PARDS subgroup at 15 minutes (12.9%, p=0.125). This interim analysis does not show a significant improvement in lung compliance following a single IPV treatment in a heterogeneous group of invasively ventilated children, although differences may not have been detected due to small sample size. It is also possible that changes in compliance would be more appreciable with multiple IPV treatments over time."

Clinical • Compliance • Acute Respiratory Distress Syndrome • CNS Disorders • Respiratory Diseases

Current Treatments for Pediatric Critical Asthma: An Interim Analysis From the CATCHUP Study (SCCM 2026) - "During hospital admission, 134 (33.7%) received ipratropium, 136 (34.2%) received intermittent IV magnesium, 52 (13.1%) received continuous IV magnesium, 45 (11.3%) received IV terbutaline, and 28 (7.0%) received IV aminophylline. Pharmacologic treatments and respiratory support management varies between patients, with ipratropium and magnesium being the most common adjunctive medications and HFNC and NIV both being common support devices used."

Clinical • Acute Lung Injury • Asthma • Immunology • Infectious Disease • Pediatrics • Respiratory Diseases • Septic Shock

The usefulness of the new SOBIstat-F® device in children with severe acute asthma attacks in the emergency department: A randomized clinical trial. (PubMed, J Asthma) - "Protocols for managing severe asthma exacerbations include bronchodilators (short-acting beta-2 agonists and ipratropium bromide) administered by nebulizer or pressurized metered-dose inhaler(pMDI) with a valved holding chamber, corticosteroids IV, and magnesium sulfate IV...Side effects were similar. For the first time, bronchodilator administration using the SOBIstat-F® device was more effective than the conventional method in reducing hospitalizations and improving the clinical condition of children with severe asthma exacerbations."

Clinical • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pulmonary infection by Nocardia saintgeorgesii mimicking lung cancer with concurrent pulmonary embolism in an immunocompetent host: a case highlighting the diagnostic role of mNGS. (PubMed, Front Cell Infect Microbiol) - "Empirical antibiotic therapy with piperacillin-tazobactam was initiated initially, supplemented with inhaled ipratropium bromide and expectorants to alleviate symptoms...The treatment regimen was then adjusted to ceftriaxone sodium combined with compound sulfamethoxazole, and the surgical schedule was canceled...Some literature suggests that many PN patients present with concurrent deep vein thrombosis (DVT), suggesting a potential yet underrecognized association between Nocardia infection and thrombotic events. However, this correlation has not been fully reported before."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Lung Cancer • Oncology • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

Efficacy of personalized multi-ingredient nasal sprays in patients with rhinitis (AAAAI 2026) - "Methods Based on symptomatology review from an online intake questionnaire, a telehealth provider prescribes a nasal spray with up to 4 of the following ingredients: triamcinolone 0.055%-0.11%, azelastine 0.137%, ipratropium 0.015%-0.09% and microdose oxymetazoline 0.003125%-0.0125% (equivalent to 1/12th to 1/48th standard otc intranasal oxymetazoline)...Post hoc individual chi-squared tests showed statistically significant improvement (p<0.05) for all symptoms except snore. Conclusions Use of Allermi Super Spray resulted in statistically significant improvement of rhinitis symptoms and highlights the efficacy of personalized, targeted multi-ingredient intranasal treatment."

Clinical • CNS Disorders • Glaucoma • Inflammation • Ophthalmology • Otorhinolaryngology • Pruritus • Sleep Disorder • Vascular Neurology

Amphastar Announces FDA Approval for Ipratropium Bromide HFA (ACCESS Newswire) - "Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with Paragraph IV certification. This exclusivity period will begin on the first day that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is commercially launched....Amphastar plans to launch its Ipratropium Bromide HFA Inhalation Aerosol, previously referred to as AMP-007, early in the second quarter of 2026."

ANDA • Generic launch • Asthma • Chronic Obstructive Pulmonary Disease • Immunology

Evaluation of artificial intelligence identified ipratropium bromide for the treatment of coronavirus disease 2019. (PubMed, Sci Rep) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Effect of Ipratropium Bromide on EILO (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Cook Children's Health Care System

New P2 trial • Pediatrics • Pulmonary Disease

More Lessons from the Lung Health Study. (PubMed, Am J Epidemiol) - "Between 1986 and 1989, the LHS enrolled 5,887 smokers aged 35-59 with mild-to-moderate airway obstruction across ten North American sites and randomized them to a 10-day smoking cessation intervention with placebo inhaler, the same intervention with ipratropium bromide, or usual care...This publication highlights the importance of trial conduct, data preservation, and the value of long-term follow-up using the National Death Index. Congratulations to the authors for this fourth update and to all LHS researchers who contributed to this landmark clinical trial."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Tobacco Cessation

Predictive Value of Ipratropium Responsiveness on Posterior Nasal Nerve Neurectomy Outcomes in Chronic Rhinitis. (PubMed, Otolaryngol Head Neck Surg) - "Patients with positive response to ipratropium may be more likely to benefit from PNN in-office ablation techniques. Ipratropium response is not predictive of outcome for surgical PNN neurectomy, as both responders and nonresponders may experience benefit."

Journal • Inflammation • Otorhinolaryngology

Eco-friendly cucurbituril-based potentiometric sensors for selective quantification of ipratropium bromide in pharmaceuticals and human plasma. (PubMed, Anal Bioanal Chem) - "The method's sustainability was evaluated using the Analytical Eco-Scale, AGREE, and RGB models, confirming its sustainable performance. The developed sensors also contribute to several United Nations Sustainable Development Goals (UN-SDGs), including those related to health, clean water, sustainable production, and innovation."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Structural basis of sodium ion-dependent carnitine transport by OCTN2. (PubMed, Nat Commun) - "Here we report cryo-EM structures of human OCTN2 in three conformations: inward-facing ligand-free, occluded carnitine- and Na+-bound, and inward-facing ipratropium-bound. These structures define key interactions responsible for carnitine transport and identify an allosterically coupled Na+ binding site housed within an aqueous cavity, separate from the carnitine-binding site. Combined with electrophysiology data, we provide a framework for understanding variants associated with SPCD and insight into how OCTN2 functions as the primary human carnitine transporter."

Journal • Metabolic Disorders

Exacerbation of Asthma Among Pediatric Patients Presenting to the Emergency Department. (PubMed, J Clin Med) - "In moderate to severe cases, ipratropium bromide is added. For refractory or life-threatening presentations, intravenous magnesium sulfate, epinephrine, or ventilatory support may be required...Post-discharge care includes thorough caregiver education, medication access, and a personalized asthma action plan to reduce recurrence risk. The effective diagnosis, appropriate exacerbation treatment, monitoring of patients in the post-attack period, as well as successful preventive medication play a key role in the management of pediatric patients with asthma."

Journal • Review • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Depression in children with asthma: Testing a cholinergically mediated "endotype". (PubMed, J Allergy Clin Immunol Glob) - "Higher depressive symptom scores are associated with increased airway responsiveness to inhaled ipratropium in children with asthma and active airway obstruction. These findings suggest the potential for definition of an endotype of asthma with comorbid depression that may benefit from anticholinergic asthma therapies."

Journal • Asthma • CNS Disorders • Depression • Immunology • Inflammation • Mood Disorders • Pediatrics • Psychiatry • Pulmonary Disease • Respiratory Diseases

Medical Management of Rhinitis: Medication Options. (PubMed, Immunol Allergy Clin North Am) - "Intranasal ipratropium, cromolyn, and decongestants offer symptom-specific relief. Oral medications such as antihistamines, leukotriene receptor antagonists, decongestants, and corticosteroids, vary in efficacy and side effects. Emerging therapies like biologics and CRTH2/DPP-4 inhibitors show promise in clinical and preclinical studies."

Journal • Review • Inflammation • PTGDR2

Use of inhaled/nebulised ipratropium bromide in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2-agonist and systemic steroid in the management of acute asthma exacerbations: a systematic review and meta-analysis of randomised controlled trials. (PubMed, Arch Dis Child) - "This review found high-certainty evidence that the IB nebuliser leads to a lower hospitalisation rate. However, when inhaled/nebulised IBs were analysed together, the hospitalisation rate was similar, with moderate certainty evidence. IB improved asthma clinical scores, with low certainty evidence. No difference was reported in other prespecified outcomes.Considering the current evidence and safety profile, inhaled/nebulised IB needs to be considered as an additional treatment for acute asthma exacerbation."

Journal • Retrospective data • Asthma • Critical care • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Effects of inhaled bronchodilators on dynamic lung mechanics during exercise in COPD: protocol for a randomised, placebo-controlled crossover trial. (PubMed, ERJ Open Res) - "A double-blind, placebo-controlled study involving 25 symptomatic patients (modified Medical Research Council score ≥2) showing functional residual capacity >120% pred and/or >upper limit of normal will receive nebulised salbutamol sulphate (2.5 mg) plus ipratropium bromide (0.5 mg) or normal saline...Confirmation of the study's hypotheses will shed new light on the mechanisms of dyspnoea improvement after inhaled bronchodilators in patients with COPD. Moreover, it will provide a novel integrative platform for assessing the effects of therapeutic approaches targeting their small airways."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Peculiar Case Of Unilateral Rhinorrhea (ACAAI 2025) - "She has tried Ipratropium, Azelastine, and Fluticasone nose sprays plus oral antihistamines without relief. The patient was referred to Neurosurgery for additional evaluation and treatment of the CSF leak. Discussion Though rare, CSF leaks can occur in the setting of presumed allergic rhinitis with a pan-positive serum allergy panel; consider it in a patient with unilateral refractory rhinorrhea that is largely positional."

Clinical • Allergic Rhinitis • Immunology • Inflammation

Vasomotor Rhinitis: Current Concepts and Emerging Therapies. (PubMed, Cureus) - "Variable therapies include corticosteroids, intranasal antihistamines, and anticholinergics, although ipratropium bromide has had the best dependability results in terms of rhinorrhea...VMR is a condition that has not been adequately studied but is common and requires a progressive management style that relies on triggers. Whereas conventional intranasal treatment is the most appropriate in the first case, nerve-specific treatment has promising outcomes in the case of relapse."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation

Predictive Value of Ipratropium Responsiveness on Posterior Nasal Nerve Neurectomy Outcomes in Chronic Rhinitis (AAO-HNSF 2025) - "Ipratropium response may not be predictive of outcomes for PNN surgical neurectomy. Both ipratropium responders and non-responders may be benefit from PNN surgical neurectomy."

Allergic Rhinitis • Immunology • Inflammation

Comparison of nebulized long-acting muscarinic antagonist (LAMA) revefenacin to short acting muscarinic antagonist (SAMA) ipratropium in COPD patients with acute respiratory failure requiring mechanical ventilation (ERS 2025) - "Nebulized revefenacin once daily in mechanically ventilated COPD patients in ARF is a feasible alternative to SAMA and reduces resource utilization for bronchodilator delivery. Ventilatory mechanics show potentially greater benefit of revefenacin than ipratropium on airway resistance."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Assessing the Feasibility of pMDI and Jet Nebulization for Bronchodilator Delivery in AECOPD Patients on NIV: A Randomized Pilot Trial (ERS 2025) - "This pilot trial demonstrates that conducting a randomized comparison of pMDI and jet nebulization for bronchodilator delivery in AECOPD patients on NIV is feasible. Higher serum ipratropium levels with pMDI suggest potential clinical advantages, warranting further investigation in a larger, definitive trial. References Dolovich MB, et al."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Amitriptyline inhibits bronchoconstriction independent of direct receptor binding and reduces number of caveolae. (PubMed, Sci Rep) - "Neither the muscarinic antagonist ipratropium nor the phospholipase C inhibitor U73122, nor the protein kinase C inhibitor chelerythrine diminished the effect of amitriptyline...Furthermore, neither simvastatin (a lipid lowering agent) nor cytochalasin D (an inhibitor of actin polymerization), influenced the inhibitory effect of amitriptyline on bronchoconstriction...A more general mechanism seems likely, as inhibition of single signal transduction pathways failed. Further studies are required to elucidate the underlying mechanisms."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Stepwise Management of Status Asthmaticus Refractory to Initial Therapy: A Case Report. (PubMed, Cureus) - "First, the patient was treated with inhaled beta-2 agonist (albuterol) and corticosteroids (prednisone, dexamethasone, and methylprednisolone). The patient did not improve with these treatments and was given the anticholinergic agent ipratropium bromide in an attempt to increase bronchodilation. Nebulized racemic epinephrine was then added to the patient to optimize maximum bronchodilation and vasoconstriction in an attempt to reduce airway edema and inflammation. To reduce ventilator peak airway pressures through sedation and paralytics, rocuronium and cisatracurium (Nimbex) were administered. Ketamine was added as a sedative and bronchodilator. Propofol and midazolam (Versed) were used to sedate the patient for mechanical ventilation. After the acute episode, maintenance therapy included inhaled corticosteroids (budesonide), a long-acting beta-2 agonist (arformoterol), a long-acting muscarinic antagonist (revefenacin), and montelukast (a leukotriene receptor..."

Journal • Anesthesia • Asthma • Cardiovascular • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Effect of Dual Bronchodilation on the Exercise Capacity of Individuals With Non-Cystic Fibrosis Bronchiectasis: Protocol for a Randomized Controlled Double-Blind Crossover Study. (PubMed, JMIR Res Protoc) - P=N/A | "There is no evidence that BDs can improve the exercise capacity of patients with NCFB. This trial will compare the endurance exercise capacity of the same individual with and without dual bronchodilation. If successful, this study will demonstrate that exercise capacity can be improved with the use of BDs in adults with NCFB."

Journal • Bronchiectasis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases